Inhibikase Therapeutics held its 2026 Annual Meeting of Stockholders on June 26, 2026. Stockholders approved an amendment to the 2020 Equity Incentive Plan to increase the number of reserved shares by 3,000,000. An amendment to the Certificate of Incorporation was approved to limit the liability of certain officers, effective June 26, 2026. Two Class III directors, Arvind Kush and Dennis Berman, were elected to the Board of Directors, serving until the 2029 annual meeting. The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. An advisory vote on the compensation of named executive officers was approved. Stockholders also voted to hold future advisory votes on executive compensation on an annual basis.